From Thursday onward, a ban on specific Apple smartwatch models will be in effect as the technology giant awaits the outcome of its appeal. Masimo, a Southern California-based company, initiated a complaint with the US International Trade Commission (ITC), resulting in the ITC’s decision in October to halt the import of particular Watch models because of a patented technology associated with detecting blood-oxygen levels Despite a temporary lift of the ban last month, it is scheduled to be reinstated.
With Apple largely manufacturing its products overseas, especially in China, the ITC holds jurisdiction over the patent dispute. In response to the ban, there are reports indicating that Apple plans to temporarily remove the contested technology from the affected smartwatches, specifically the Series 9 and Ultra 2—a move welcomed by Masimo.
Masimo asserts itself as the original inventor of the technology, alleging that Apple recruited key employees to obtain access to this knowledge. Apple challenges the ITC’s decision, claiming it was flawed and should be reversed. The tech giant has filed an appeal in the federal appeals court, a process that could extend for a year or more before a resolution is reached.
Joe Kiani, Masimo’s CEO, views the implementation of the ban as a “victory” for the US patent system, underscoring that even formidable companies like Apple must respect intellectual property rights. Apple, as of now, has not responded to queries from AFP on this matter.
